Magnetic resonance imaging (MRI) has a well-established role as a highly specific and accurate modality for characterizing benign and malignant focal liver lesions. In particular, contrast-enhanced MRI using hepatocyte-specific contrast agents (HSCAs) improves lesion detection and characterization compared to other imaging modalities and MRI techniques. In this pictorial review, the mechanism of action of gadoliniumbased MRI contrast agents, with a focus on HSCAs, is described. The clinical indications, protocols, and emerging uses of the 2 commercially available combined contrast agents available in the United States, gadoxetate disodium and gadobenate dimeglumine, are discussed. The MRI features of these agents are compared with examples of focal hepatic masses, many of which have been obtained within the same patient therefore allowing direct lesion comparison. Finally, the pitfalls in the use of combined contrast agents in liver MRI are highlighted.
Magnetic resonance imaging (MRI) of the liver routinely employs the use of gadolinium-based contrast agents in order to increase conspicuity and facilitate characterization of focal lesions. Each category of contrast agent offers different properties, which may be tailored to answer a specific clinical question.
Extracellular gadolinium-containing agents consist of gadolinium chelated to an organic compound. Gadolinium shortens the T1 and T2 relaxation times, leading to increased T1 signal intensity. They demonstrate vascular perfusion by distributing into the extracellular fluid compartment and are predominantly renally excreted. Differential vascular perfusion between normal liver parenchyma and focal hepatic lesions enables characterization. In the cirrhotic liver, however, heterogeneous background enhancement may obscure focal lesions [1] .
Hepatocyte-specific contrast agents (HSCAs) distribute initially into the extracellular fluid compartment, are subsequently taken up by functioning hepatocytes and then excreted into biliary canaliculi along the same pathway as bilirubin [2] . Based on gadolinium, these agents cause T1 shortening of the liver and biliary tree and enable comprehensive noninvasive imaging in both the dynamic and hepatocyte phases [3] . As a result of these properties, HSCAs enable differentiation of hepatocellular and nonhepatocellular lesions, the latter of which demonstrate increased conspicuity on delayed T1 images compared to background parenchyma [1] .
The pharmacologic characteristics of the 2 commercially available HSCAs in the United States, gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy) and gadoxetate disodium (Eovist or Primovist; Bayer Schering Pharma, Berlin, Germany) are outlined in Table 1 . A suggested protocol for performing MRI of focal hepatic lesions with HSCAs is included in Table 2 .
Gadoxetate disodium possesses slightly different properties than both extracellular contrast agents and gadobenate dimeglumine. The arterial phase appears less intense than with conventional extracellular agents [2] . Strategies to optimize the arterial phase of gadoxetate disodium include injection strategies, such as reducing the injection flow rate and diluting the contrast agent, and fluoroscopic or bolus triggering techniques [4] . Of note, a subset of patients may experience acute transient dyspnea following intravenous injection of gadoxetate disodium, which results in more severely motion degraded images than with gadobenate dimeglumine [5] . Table 2 Magnetic resonance imaging protocol for assessment of focal liver lesions T1-weighted in-phase and opposed-phase imaging T2-weighted fast spin echo magnetic resonance cholangiopancreatography (optional) Unenhanced T1-weighted fat-saturated GRE (optional) T1-weighted fat-saturated hepatic arterial phase or triple arterial phase GRE T1-weighted fat-saturated portal venous phase GRE T1-weighted fat-saturated late venous phase GRE Diffusion-weighted imaging (optional) T2-weighted fast spin echo (with or without fat saturation) T1-weighted fat-saturated hepatocellular phase GRE GRE ¼ gradient recalled echo. Hepatocyte uptake occurs rapidly and liver parenchymal enhancement may be seen as early as 90 seconds following injection; due to greater hepatic uptake, there is more intense hepatocyte phase enhancement compared to gadobenate dimeglumine [6, 7] . Similarly, rapid hepatocyte clearance of gadoxetate disodium causes the vessels to become hypointense compared to liver parenchyma as soon as 10 minutes postinjection [6] . Hepatocyte phase imaging is generally performed following a 20-minute delay, compared to 1-2 hours with gadobenate dimeglumine. Impaired gadoxetate disodium uptake in the cirrhotic liver reduces hepatocyte phase enhancement and therefore protocol adjustments may be needed to improve image quality [7e9]. Indeed, peak hepatocyte phase enhancement may be delayed beyond the conventional 20 minutes and may take 40 minutes or more [10] . Significantly higher enhancement ratio has been reported in patients with Child-Pugh class A disease compared to Child-Pugh class C disease [4] . Moreover, initial studies suggest improved lesion-to-liver contrast ratio in the cirrhotic liver with a dose increase from the standard 0.025 mmol/kg to an off-label dose of 0.05 mmol/ kg [11] .
MRI Findings in Focal Hepatic Lesions Using HSCAs
The typical MRI findings of focal liver lesions using HSCAs are summarized in Table 3 .
Liver MRI is often used to distinguish 2 benign focal hepatic lesions, nodular hyperplasia (FNH) and adenoma. Although FNH is often managed conservatively, adenomas require more frequent monitoring or resection due to risk of rupture, hemorrhage or malignant transformation. In the absence of typical features, however, FNH and adenoma may be challenging to distinguish using extracellular contrast Figure 1 . Focal nodular hyperplasia in a 40-year-old woman. Gadoxetate disodium magnetic resonance imaging demonstrates iso-to hypointensity on T1-weighted imaging, isointensity on T2-weighted imaging, intense arterial phase enhancement, hyperintensity of the portal venous and transitional phases, and iso-to mild hyperintensity on the hepatocyte phase (arrows). This figure is available in colour online at http://carjonline.org/. agents: for example, only approximately half of FNHs demonstrate the classic T2 hyperintense scar and a similar proportion of adenomas contain intratumoural fat [12] . Moreover, a minority of adenoma demonstrates a central enhancing scar, a finding more typically observed in FNH [13] .
Focal Nodular Hyperplasia
FNH is a benign neoplasm characterized histopathologically by increased density of normal functioning hepatocytes and abnormal blind-ending biliary ductules, which demonstrate delayed biliary excretion compared to normal liver parenchyma. Risk of rupture and hemorrhage is small and no malignant potential has been reported [14] .
FNH is typically iso-to hypointense to background liver parenchyma on T1; iso-to slightly hyperintense on T2-weighted images and hypervascular and fade to isointensity on the portal venous and late dynamic phases (Figures 1 and 2 ). Hepatocyte phase enhancement is commonly homogeneously iso-to hyperintense due to contrast retention within hepatocytes ( Figures 1 and 2) ; less common patterns include iso-or hypointense and heterogeneous or peripheral enhancement [12] . Slower uptake is seen in the central scar, which remains hypointense on hepatocyte phase using gadoxetate disodium compared to hyperintense with extracellular agents [3] . Gadobenate dimeglumine enables discrimination of adenoma from FNH with a high degree of confidence: lack of uptake in adenomas leads to hepatocyte phase hypointensity while uptake in FNHs leads to iso-or hyperintensity ( Figure 2 ) [12, 15] .
Hepatic Adenoma
Hepatic adenoma is a less common benign neoplasm characterized histopathologically by cords of hepatocytes separated by sinusoids. Adenomas lack portal and central veins as well as biliary ductules and normal biliary excretion is therefore impaired.
Adenomas may demonstrate heterogeneous hyperintensity on T1-weighted images due to the presence of hemorrhage or intralesional fat. Dynamic phase enhancement of adenomas with HSCAs is similar to extracellular agents and typically demonstrates hypervascularity with isointensity observed on the portal venous and transitional (late dynamic) phases (Figures 3 and 4) [16] . With the exception of inflammatory adenomas, discussed subsequently, no hepatocyte phase enhancement is observed using gadobenate dimeglumine, whereas variable enhancement may occur with gadoxetate disodium [12, 15] .
Recent advances in molecular studies have led to the reclassification of the telangiectatic focal nodular hyperplasia as inflammatory subtype of hepatic adenoma [17, 18] . They represent the most common adenoma subtype, accounting for approximately 40%-50%, a subset of which may demonstrate imaging features that overlap with FNH [18] . Inflammatory adenomas are hypervascular masses that demonstrate persistent enhancement on portal venous and delayed phases and are typically iso-to mildly T1 hyperintense and T2 hyperintense [19] . Hepatocyte phase enhancement using gadoxetate disodium demonstrates iso-to hyperintense compared to background parenchyma [18] . A distinguishing feature identified in approximately half of cases is a band of peripheral T2 hyperintense signal with central isointensity, the so-called atoll sign, with small T2 hyperintense lesions often seen at the centre of the lesion (Figure 5 ), a finding not clearly demonstrated in the remaining adenoma subtypes [20] . 
Cavernous Hemangioma
Histopathologically, cavernous hemangiomas are characterized by large vascular channels separated by thin septations. Hemangiomas are typically T1 hypointense and T2 hyperintense; dynamic phase imaging demonstrates discontinuous peripheral hyperintensity with centripetal progression. Because they lack hepatocytes, hemangiomas typically appear hypointense to normal hepatic parenchyma in the hepatocyte phase; however, subtle central hyperintensity may be observed beyond the dynamic phase due to progressive centripetal contrast accumulation.
Caution is advised when using gadoxetate disodium in known or suspected hemangiomas: the arterial phase is typically less intense and the characteristic peripheral contrast puddling observed with extracellular contrast agents may be obscured due to intense hepatocyte uptake, which may be seen as early as the portal venous and transitional phase ( Figures 6   and 7) . As a result, hemangiomas may demonstrate avid arterial enhancement and subsequently appear hypointense to normal liver parenchyma as early as 3 minutes following injection due to rapid progressive hepatic parenchymal enhancement [2] . This leads to a ''pseudo-washout'' phenomenon, which may cause high flow hemangiomas to mimic hypervascular tumours ( Figures 6 and 7 ) [21] . To distinguish these entities, the characteristic high T2 signal intensity, arterial phase enhancement, and pseudo-washout sign during the transitional phase have been suggested to favor a diagnosis of hemangioma [21] .
Hepatic Metastases
Hepatic metastases from extrahepatic malignancies are typically T1 hypointense and T2 hyperintense and may be hypo-or hypervascular on dynamic phase imaging (Figures 8  and 9 ). Histopathologically, hepatic metastases lack Figure 7 . Cavernous hemangioma in a 47-year-old woman. Gadoxetate disodium enhanced magnetic resonance imaging demonstrates unique subtle arterial enhancement, early contrast uptake by surrounding hepatocyte uptake that may obscure characteristic puddling, hypointensity (''pseudo-washout'') of the hemangioma on the transitional phase, and hypointensity on the hepatocyte phase (arrows). This figure is available in colour online at http://carjonline.org/.
functioning hepatocytes or bile ducts and therefore remain uniformly hypointense compared to normal enhancing liver during the hepatocyte phase ( Figure 9 ) [2, 3] . A ''target sign'' of central round enhancement with peripheral low signal rim may also be observed in the hepatocyte phase [22, 23] . A thin, hyperintense rim may be seen at the interface between the metastasis and normal liver, which may represent compressed normal liver, biliary reaction, or both [2] .
Both gadobenate dimeglumine and gadoxetate disodium reliably detect small, subcentimeter hepatic metastases compared to computed tomography (CT), which enables more accurate preoperative assessment of candidates for curative liver resection [24e26]. Indeed, a recent metaanalysis of the diagnostic performance of gadoxetate disodium in the detection of hepatic metastases from colorectal carcinoma demonstrated an overall sensitivity of 93% and sensitivity of 95% [27] . Gadobenate dimeglumine has also shown a statistically significant improvement in the detection rate and positive predictive value of identifying colorectal metastases compared unenhanced or conventional contrastenhanced MRI [25] . In the postchemotherapy patient, MRI demonstrates superior diagnostic performance over CT, positron emission tomography, and positron emission tomography/CT in the detection of metastases [28] ; moreover, gadoxetate disodium-enhanced MRI demonstrated superior performance to CT in detecting subcentimeter colorectal hepatic metastases in the preoperative evaluation of patients with hepatic steatosis [29] .
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) typically demonstrates arterial enhancement with portal venous and transitional phase washout. Due to the reduced expression of membrane cotransporters necessary for enhancement, HCCs usually remain hypointense relative to background parenchyma in the hepatocyte phase [2] (Figures 10 and 11) . A diagnostic pitfall with the use of gadoxetate disodium in a minority of HCCs is paradoxical uptake, whereby the lesion appears isoor hyperintense compared to liver parenchyma, attributable to increased expression of membrane transporters in moderately or well-differentiated lesions [10,30e32] . As a result of this paradoxical uptake, these hyperintense HCCs may be difficult to detect or be mistaken for benign cirrhosisassociated nodules ( Figure 12 ) [15, 33] .
Identification of small HCCs remains a diagnostic challenge, particularly given the less intense arterial phase and respiratory motion artifact observed in some patients following injection of gadoxetate disodium. Advantages of using gadoxetate disodium include significantly greater diagnostic performance over both contrast-enhanced CT and conventional dynamic MRI in evaluating small early HCCs [34e36]. In addition, 4 statistically significant findings associated with small HCCs have been demonstrated using gadobenate dimeglumine: hyperintensity during the arterial phase, hypointensity during the portal venous and hepatocytes phases, and hyperintensity on T2-weighted images [37] .
Cholangiocarcinoma
Cholangiocarcinoma originates from the biliary epithelium as adenocarcinoma, papillary carcinoma, or mucinous carcinoma and may arise within the intra-or extrahepatic bile ducts. Mass-forming cholangiocarcinoma is typically T1 hypointense and mild to moderately T2 hyperintense, depending on the amount of fibrous tissue and mucin, with delayed washout observed with extracellular agents. Additional findings include biliary duct dilatation and atrophy and capsular retraction of the involved segment. Arterial phase imaging with gadoxetate disodium may demonstrate irregular peripheral rim enhancement [3] . Due to hepatic uptake using HSCAs, cholangiocarcinoma appears hypointense to background liver in the transitional and hepatobiliary phases (Figure 13 ) [4] . As a result, gadoxetate acid-enhanced MRI has been shown to be a reliable method to assess bile duct tumour resectability, with accuracy in a retrospective review of up to 84% [38] .
Hepatic epithelioid hemangioendothelioma
Hepatic epithelioid hemangioendothelioma is a rare vascular tumour characterized histopathologically by Figure 9 . Treated hepatic metastases in a 59-year-old woman with history of pancreatic neuroendocrine tumour. Gadoxetate disodium enhanced dynamic imaging demonstrates numerous arterially enhancing lesions, 1 of which is demonstrated within segment VI, which fades to hypointensity by the portal phase and remains hypointense on the hepatocyte phase (arrows). The lesion also shows mild T2 hyperintensity and evidence of restricted diffusion (arrows). Given the background history of pancreatic neuroendocrine tumour, the findings of multiple hyperenhancing lesions favor a diagnosis of hypervascular metastatic lesions. The differential includes multifocal hepatocellular carcinoma, but is less likely in the absence of underlying cirrhosis. DWI ¼ diffusion-weighted imaging. This figure is available in colour online at http://carjonline.org/. Figure 10 . Hepatocellular carcinoma in a 70-year-old man with known cirrhosis. Gadoxetate disodium enhanced T1 dynamic imaging demonstrates a focal 2 cm arterially enhancing lesion in segment VI, which fades to hypointensity by the portal phase and remains hypointense on the hepatocyte phase (yellow arrows). The lesion shows mild T2 hyperintensity and evidence of restricted diffusion (yellow arrows). The findings are diagnostic of hepatocellular carcinoma in this patient with a background of cirrhosis. Note the large portocaval shunt on the medial aspect of the lesion, demonstrating flow void on T2 sequence (red arrow). DWI ¼ diffusion-weighted imaging. This figure is available in colour online at http://carjonline.org/. epithelioid and dendritic cells with central fibrotic stroma. Lesions may be single or multiple, typically peripheral in location with associated capsular retraction. Hepatic epithelioid hemangioendothelioma lesions are typically T1 hypointense and T2 hyperintense with ring or target-like enhancement following extracellular contrast administration [39, 40] . Progressive centripetal fill-in on dynamic postcontrast sequences has been observed ( Figure 14 ) [40] . Hepatobiliary phase imaging using gadoxetate acid demonstrates homogeneous or target-shaped hypointensity [40] .
Nodules in the cirrhotic liver
A spectrum of nodules may be seen in the cirrhotic liver. Hemodynamic changes and fibrosis may cause heterogeneous enhancement, making differentiation of benign regenerative nodules and premalignant dysplastic nodules from HCC challenging [41, 42] . Furthermore, impaired hepatocyte function may limit contrast uptake, leading to decreased distinction between the focal lesion and background parenchyma. Regenerative and dysplastic nodules typically demonstrate portal venous phase enhancement to become iso-or hyperintense to background liver parenchyma. Iso-to hyperintense hepatocyte phase enhancement is observed due to preserved hepatocellular function and intact ion transporters [28, 29] . With increasing atypia, as with poorly differentiated dysplastic nodules, there is decreased expression of ion transporters and reduced ability to take up gadoxetate disodium, with subsequent hypointensity observed on the hepatocyte phase [10] . Figure 11 . Infiltrative hepatocellular carcinoma in a 64-year-old man with chronic hepatitis (B) Gadoxetate disodium enhance magnetic resonance imaging demonstrates an expansile mass lesion occupying the left hepatic lobe (arrows), which demonstrates T1 hypointensity and T2 hyperintensity compared to background liver parenchyma. There is mild, heterogeneous arterial enhancement with washout in the portal venous and transitional phases. The mass remains hypointense to background liver on the hepatocyte phase. This figure is available in colour online at http://carjonline.org/.
A retrospective study of 34 patients with 29 surgically resected HCCs and 31 benign nodules using gadoxetate disodium suggested the following imaging criteria to differentiate HCC from premalignant nodules: size 1.5 cm, hypointense on T1-weighted images, hyperintense on T2and diffusion-weighted images, hyperenhancement on the arterial phase, and hypointensity on the portal venous and hepatocyte phases [43] . Lesions were considered malignant if they satisfied 3 or more of these criteria; sensitivity was higher than arterial enhancement and washout alone. In addition, a retrospective study of hypervascular hepatic lesions using gadobenate dimeglumine demonstrated that all 82 regenerative nodules were iso-or hyperintense on the hepatocyte phase, which suggests this may be used as a Figure 12 . Well-differentiated hepatocellular carcinoma versus highly dysplastic nodule in a 59-year-old woman with known cirrhosis. The lesion shows mild T2 hypointensity and is isointense on precontrast T1 imaging. Gadoxetate disodium enhanced T1 dynamic imaging demonstrates arterial enhancement, which fades to hypointensity by the portal phase and becomes slightly hyperintense to surrounding hepatocytes on transitional phase (arrows). The lesion is hyperintense on the hepatocyte phase (arrow). Uptake of gadoxetate disodium in the hepatocyte phase can occur in a small percentage of well-differentiated hepatocellular carcinoma. Short interval follow-up imaging was recommended. This figure is available in colour online at http://carjonline.org/. Figure 13 . Cholangiocarcinoma in a 59-year-old woman. Gadoxetate disodium enhanced magnetic resonance imaging demonstrates an ill-defined mass in the region of the left porta hepatis (arrows), which is T1 hypointense compared to liver parenchyma. There is mild arterial and portal venous phase postgadolinium enhancement, with hypointensity to background liver parenchyma on the hepatocyte phase. Biliary ductal dilatation is noted adjacent to the mass. This figure is available in colour online at http://carjonline.org/. Figure 14 . A 22-year-old woman with hepatic epithelioid hemangioendothelioma. Gadoxetate-disodium enhanced magnetic resonance imaging demonstrates multiple hepatic lesions, some of which coalesce peripherally (arrows), primarily involving the right hepatic lobe. These lesions are moderately T2 hyperintense and T1 hypointense with no postgadolinium enhancement. The lesions remain hypointense on the hepatocyte phase. This figure is available in colour online at http://carjonline.org/. feature of lesion benignity ( Figure 15 ) [44] . Finally, the combination of dynamic and hepatocyte phase gadoxetate disodium-enhanced MRI has been shown to provide incremental value over conventional dynamic phase MRI alone in characterizing focal liver lesions in the cirrhotic liver [45] .
Conclusions
Owing to their unique pharmacologic properties, MRI using HSCAs enables comprehensive evaluation of focal liver lesions in both the dynamic and hepatocyte phases. This offers improved lesion conspicuity and characterization over other imaging modalities and conventional extracellular gadolinium-based contrast agents. In particular, HSCA offer unique advantages in differentiation of hepatocellular from nonhepatocellular lesions, detection of hepatic metastases and distinction between hepatic adenoma and focal nodular hyperplasia. Familiarity with the uses, findings and pitfalls of the 2 commercially available HSCAs, gadoxetate disodium and gadobenate dimeglumine, is essential to image interpretation and patient management.
